Faecal Microbiota Transplant: The Science Behind Poo Transplants

<![CDATA[

It might sound like the setup to an uncomfortable joke, but faecal microbiota transplant (FMT)—colloquially known as a “poo transplant”—represents one of the most remarkable medical breakthroughs of recent decades. The premise is simple, if slightly stomach-churning: take stool from a healthy donor, process it, and introduce it into the gut of a sick patient. The results? Nothing short of extraordinary.

What Is Faecal Microbiota Transplant?

FMT involves transferring the complete microbial ecosystem from a healthy donor’s gut into a recipient’s digestive system. Your gut microbiome contains trillions of bacteria, viruses, fungi, and other microorganisms that play crucial roles in digestion, immunity, and even mental health. When this ecosystem becomes severely disrupted—a state called dysbiosis—simply adding one or two probiotic strains often isn’t enough. FMT takes the radical approach of replacing the entire community.

Think of it like this: if your garden has been overrun by weeds, you could try planting a few flowers and hope they compete. Or you could clear the soil and transplant an entire established ecosystem. FMT opts for the latter approach.

The C. difficile Success Story

The condition that put FMT on the medical map is Clostridioides difficile infection (CDI). This opportunistic bacterium typically takes hold after antibiotics have decimated the normal gut flora, causing severe diarrhea, colitis, and in serious cases, death. Recurrent CDI—where the infection keeps returning despite antibiotic treatment—affects hundreds of thousands of people annually.

Standard antibiotics for recurrent CDI have success rates around 20-30% after multiple episodes. FMT? Studies consistently show cure rates exceeding 90%. A 2013 randomized trial was actually stopped early because FMT was so dramatically more effective than vancomycin that it would have been unethical to continue denying it to the control group.

These results represent one of the most successful therapies in modern medicine for any condition. The transformation can be remarkable—patients who’ve been housebound for months due to severe CDI often recover within days of transplantation.

How It Works: The Procedure

Donor Screening

Not just anyone can donate stool for FMT. Rigorous screening eliminates candidates with infectious diseases, gastrointestinal conditions, recent antibiotic use, high-risk behaviours, autoimmune diseases, and metabolic disorders. Blood and stool tests check for HIV, hepatitis, parasites, antibiotic-resistant bacteria, and numerous other pathogens. Only about 3-4% of potential donors typically pass all screening requirements.

Preparation Methods

Fresh stool is mixed with saline or another solution and filtered to create a homogeneous suspension. The mixture may be used fresh or frozen for later use. Frozen preparations have shown comparable efficacy to fresh material, which has enabled the development of stool banks.

Delivery Routes

FMT can be delivered through several methods:

• Colonoscopy: Direct delivery to the colon, most commonly used for CDI
• Enema: Less invasive, can be self-administered in some cases
• Nasoduodenal tube: A tube through the nose to the small intestine
• Capsules: Frozen material in acid-resistant capsules—more on this shortly

Enter the “Crapsule”

The development of oral FMT capsules—inevitably nicknamed “crapsules”—represents a significant advance in making the treatment more accessible and less invasive. These acid-resistant capsules contain frozen, processed stool material and are swallowed like any other pill. A typical treatment might involve 15-30 capsules taken over one or two days.

While early studies show capsules are slightly less effective than colonoscopy delivery for CDI (around 80-85% vs 90%+ cure rates), they’re far more convenient and avoid the risks and costs of an invasive procedure. For many patients, this trade-off is worthwhile.

Beyond C. difficile: Expanding Research

The success in CDI has sparked enormous interest in whether FMT might help other conditions linked to gut dysbiosis:

Inflammatory Bowel Disease

Studies in ulcerative colitis have shown modest but real benefits, with some patients achieving remission. Results in Crohn’s disease have been less consistent. The field is still determining optimal protocols—single vs multiple infusions, donor selection criteria, and maintenance approaches.

Irritable Bowel Syndrome

Some trials show improvement in IBS symptoms following FMT, particularly in patients with diarrhea-predominant IBS. However, results have been variable, suggesting we need to better understand which patients might benefit.

Metabolic Conditions

Research into FMT for obesity and metabolic syndrome has produced intriguing results. Some studies show improved insulin sensitivity following FMT from lean donors, though weight loss effects have been minimal. The research suggests gut microbes play a role in metabolism, even if manipulating them for weight loss isn’t straightforward.

Neurological and Psychiatric Conditions

The gut-brain axis has led researchers to explore FMT for conditions including autism spectrum disorder, Parkinson’s disease, and depression. Early studies show some promising signals, particularly in reducing certain autism-associated behaviours in children and improving motor symptoms in Parkinson’s. These areas remain highly experimental but illustrate how profoundly microbial diversity might influence human health.

The OpenBiome Story

The non-profit stool bank OpenBiome, founded in 2012, transformed FMT from an ad hoc procedure (often using relatives’ donations processed in hospital basements) into a standardized treatment. At its peak, OpenBiome supplied material for over 50,000 treatments. Their rigorous screening protocols and quality standards helped establish FMT as a legitimate medical therapy.

However, the landscape has shifted. The FDA’s approval of Rebyota (fecal microbiota, live-jncm) in 2022 and Vowst (fecal microbiota spores, live-brpk) in 2023—the first FDA-approved FMT products—marked a transition toward commercial, manufactured alternatives. OpenBiome has since wound down its stool bank operations, passing the torch to pharmaceutical products.

The Move Toward Defined Communities

Rather than transplanting undefined stool containing thousands of species, researchers are developing “defined microbial communities”—carefully selected consortia of specific bacterial strains. This approach offers several advantages:

• Standardized, reproducible products
• No risk of transferring unknown pathogens
• Potentially optimized for specific conditions
• Easier regulatory pathway

Products like Vowst contain purified Firmicutes spores rather than complete stool. While early results suggest these defined products may be slightly less effective than traditional FMT for CDI, they’re far safer from a regulatory and infectious disease standpoint.

Regulatory Status Around the World

FMT exists in a regulatory grey zone in many countries:

• United States: FDA considers FMT an investigational new drug but exercises enforcement discretion for CDI treatment. Approved products now available.
• United Kingdom: Regulated as a medicine when used clinically, requiring compliance with Human Tissue Authority standards
• Australia: TGA regulates FMT as a biological medicine; standardized protocols in development
• European Union: Regulatory approaches vary by country, with some considering it a medicine and others a tissue transplant

Understanding the Risks

FMT is generally considered safe for CDI treatment, but it’s not without risks:

• Infection transmission: Despite screening, there have been rare cases of serious infections transmitted through FMT, including one death from drug-resistant E. coli
• Unknown long-term effects: We don’t fully understand what happens when you transplant one person’s microbiome into another long-term
• Procedure-related risks: Colonoscopy and sedation carry their own small risks
• Unpredictable outcomes: Microbiome testing is advancing, but we can’t yet predict exactly how a recipient will respond to a particular donor’s microbiome

The COVID-19 pandemic added another layer of complexity, with concerns about potential transmission requiring additional donor screening.

The Future of FMT

The field is evolving rapidly. We’re likely to see:

• More defined microbial products replacing traditional FMT
• Better understanding of which patients respond to which approaches
• Personalized “designer” microbial communities tailored to individual conditions
• Expansion into new therapeutic areas as research matures

What started as a somewhat desperate, unconventional treatment has matured into a legitimate frontier of medicine. Yes, it involves transplanting poo—but when that poo contains a complex ecosystem capable of curing otherwise intractable infections, the “yuck factor” becomes a small price for transformation.

The science behind FMT reminds us that we’re not individual organisms but ecosystems, and sometimes the best medicine comes from restoring the community of microbes we were always meant to host.

]]>